Driven by our passion for patients and grounded in our industry-leading pipeline of 45+ different compounds across 70+ development programs, Novartis is rapidly advancing novel cancer treatment approaches in areas of great medical need.

Basel, May 12, 2022 — Novartis highlights data from across its oncology portfolio at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2022 Hybrid Congress. With nearly 130 abstracts from Novartis-sponsored and investigator-initiated trials accepted, the data showcase…

Basel, May 5, 2022 — Novartis today announced a temporary, voluntary suspension of production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey. The company has taken this action out of an abundance of caution as it addresses potential quality issues identified in its manufacturing processes. Novartis is…

Basel, May 5, 2022 — Novartis today announced the European Commission (EC) has approved Jakavi (ruxolitinib) for the treatment of patients aged 12 years and older with acute or chronic GvHD who have inadequate response to corticosteroids or other systemic therapies.

Basel, May 4, 2022 — Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. The analysis of…

Basel, May 4, 2022 — Novartis announced today that the European Commission (EC) has approved Kymriah® (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. The approval follows a positive opinion in March by the Committee…

Basel, April 27, 2022 — Novartis today announced positive topline results from an interim analysis of the Phase III RATIONALE 306 study, which showed anti-PD-1 immune checkpoint inhibitor tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally…

Basel, April 22, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended granting marketing authorization of Tabrecta® (capmatinib) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC)…

Basel, April 11, 2022 — Novartis today announced promising clinical data for JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor at the annual meeting of American Association for Cancer Research (AACR). Comprehensive information on the discovery of JDQ443 is also included in a poster being presented on…

Basel, April 6, 2022 — Novartis today announced that the European Medicines Agency (EMA) validated Marketing Authorization Applications (MAAs) for the immune checkpoint inhibitor tislelizumab for adults with:

Basel, April 6, 2022 — Novartis today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.1 Vijoice is the first…

Basel, March 25, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the European Commission to approve Kymriah® (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r)…